Asset Details
Do you wish to reserve the book?
Equitable access to essential medicines to treat neglected tropical diseases: Latest developments from the World Health Organization (WHO)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Equitable access to essential medicines to treat neglected tropical diseases: Latest developments from the World Health Organization (WHO)
Do you wish to request the book?
Equitable access to essential medicines to treat neglected tropical diseases: Latest developments from the World Health Organization (WHO)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Equitable access to essential medicines to treat neglected tropical diseases: Latest developments from the World Health Organization (WHO)
2025
Overview
In July 2023, the World Health Organization (WHO) released the 23rd Model List of Essential Medicines (EML) for adults and the 9th Model List of EML for children. These lists serve as global references for essential medicines that should be universally available, accessible, and affordable. This editorial explores recent updates to the WHO EML lists, with a particular focus on medicines addressing neglected tropical diseases (NTDs). We discuss the persistent barriers to equitable access, including economic, regulatory, and logistical challenges; highlight global initiatives aimed at improving accessibility; and propose strategies to bridge the gap in essential medicine access. We emphasize the need for international collaboration, increased funding for research institutions, pharmaceutical companies, and global health initiatives to support the development of novel treatments for NTDs, and innovative distribution approaches to ensure these medications reach underserved populations.
Publisher
Public Library of Science,Public Library of Science (PLoS)
